****

**Press Release**

**Media Contacts:**

**IB Communications**

Tel +44 (0)20 89434685

orgenesis@ibcomms.agency

**Orgenesis achieves revenue of USD 8.0 million for the third quarter of 2022**

* **Secures up to USD 50 million of funding from Metalmark Capital Partners expected to accelerate rollout of point-of-care services**
* **Reduces operating expenses by 49 percent to achieve nearly breakeven income from operation for the third quarter of 2022**
* **Orgenesis to host conference call on Friday, November 11, 2022 at 8:00 AM Eastern Time**

**Germantown**, **Maryland**, **US, November 11, 2022 -** **[Orgenesis Inc](https://click.agilitypr.delivery/ls/click?upn=UbtWP9mxrAkz4-2Bt4ix9ULCmFWwZdnFtxfDAeRaCMLDMdFqUEgQsKgcJtA0IQQ9JC-2B5ch990q4NaqAiudNJjL1kegzbcS60T2hWtkKabkyh8BwA1IzDo0QL6AO8VPYkf8vx-2FWhBcGf9Gc5kLvFB52TseuvilYRLOVLo3Zvi7rcuA9nkycLRDufnDALF-2BpMozalPWg_znnZXbWgCmE6yyN6uT5fSc4ButwtT0xdWiNHb-2B0VwM8HtF55HA6-2FW4jtQLZIHeIwySlA7p66Ret-2BKrINhFbOjX3Fn4dO1sNMhND1d7bv9xX965ZdQy07JizLtLy9rRj4i53HT-2BHJIiDoNz4o3-2BxJ56-2BaEyV6F3lZD0w-2FPQ-2BBAfqgPGyMyTUiksuKBKvtFUiE7pCmX29XBqlIyqygoKD87RXGA6o1RTKGLqt2QW7AcOglwmA0TQrezYMYFVi19WtZ8UuLwu4Q1qYGPOlNRFagOXT3eNwj2sYi8MjHd2h8-2BbSnyWpOCcleipHJsSlYrNb-2FfUZ639JqZbMFYf-2BtIFzHkAcfrxl82jfdECQrYyVW6DcZC21bEXRyg6EerhhiBgqYCqxE7NxfsXJDcELgZ7aw-2FEyaugxDVgVw9DoccRWuJgpxrNYQkIcgQBAiBRqdrrxBJYGLmrPkKewZcmMHEL4EKQ-3D-3D). (NASDAQ: ORGS)** (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for third quarter ending September 30, 2022.

Vered Caplan, CEO of Orgenesis, said, “We have made significant progress in advancing the rollout of our POCare platform. As recently announced, we secured up to USD 50 million in funding from Metalmark Capital Partners, a premier private equity firm, into a recently formed point-of-care services subsidiary, Morgenesis LLC. This transaction was highly strategic for the Company and we believe that it provides further validation of our business model. Notably, Metalmark valued this one subsidiary alone at a pre-money valuation of USD 125 million for its investment, which represents a significant premium to the market cap of our entire company. Moreover, this investment structure allowed us to fund the POCare services business, while minimizing dilution given the current state of the public markets.”

“We are highly encouraged by industry feedback related to our POCare platform. There is a shortage of production capacity in the cell and gene therapy space, and we believe that our process is far more scalable and cost-effective than the traditional centralized CDMO (Contract Development and Manufacturing Organization) model. Moreover, our POCare platform addresses many of the key challenges facing the industry, including capacity constraints and excessive costs. We believe our model is uniquely positioned to address these challenges through a highly innovative decentralized model, which lowers costs, streamlines logistics, and expands capacity.”

“While we are pleased to have achieved revenue of approximately USD 8.0 million for the third quarter, we were limited by capital constraints. With Metalmark’s support, we look forward to capitalizing on the broad demand and accelerating the deployment of our Orgenesis Mobile Processing Units and Labs (OMPULs) to potentially bring lifesaving treatments to patients across North America, Europe, Asia, and the Middle East.”

“It is important to note that separate from Morgenesis, we have a deep therapeutics pipeline in various stages of development. These programs span immuno-oncology, anti-viral, metabolic/auto-immune diseases, and tissue regeneration, and we have established co-development partnerships to help pay for their development. As these programs progress, we expect to increasingly benefit from revenue sharing and royalty agreements with our partners as we seek to advance the respective therapies through commercialization. Through these partnerships and prudent cash management, we have dramatically reduced our selling, general and administrative expenses by 49 percent and our net loss by 86 percent. As a result, we achieved nearly breakeven income from operations for the third quarter of 2022. Overall, we have built a scalable, high-margin, recurring revenue business model."

The complete financial results for the third quarter of 2022 are available on the Company’s [website](https://click.agilitypr.delivery/ls/click?upn=UbtWP9mxrAkz4-2Bt4ix9ULCmFWwZdnFtxfDAeRaCMLDMdFqUEgQsKgcJtA0IQQ9JCi-2BzpDhSBAgsuPqmNupci2YNuyV1lig0sWe-2FfWIC89df6xv8wA5AJSHI4LTbPIDpcWQ1MlPojp7LG2nrZRDWtzgfHOfcMbX-2FhnX7nPlDt33yUWeMXgX6WnS36N4F54hMpo-2BVC8kzy2QzMicn17Sxo5NUdnBvanKC4LWnX4Z0Fwfk-3DbcoU_znnZXbWgCmE6yyN6uT5fSc4ButwtT0xdWiNHb-2B0VwM8HtF55HA6-2FW4jtQLZIHeIwySlA7p66Ret-2BKrINhFbOjX3Fn4dO1sNMhND1d7bv9xX965ZdQy07JizLtLy9rRj4i53HT-2BHJIiDoNz4o3-2BxJ56-2BaEyV6F3lZD0w-2FPQ-2BBAfqgPGyMyTUiksuKBKvtFUiE7pCmX29XBqlIyqygoKD87RXGA6o1RTKGLqt2QW7AcOglwmA0TQrezYMYFVi19WtZ8UuLwu4Q1qYGPOlNRFagORY-2BdLSC6OU6FM84Hym64AjUpazZZLvvZPYDVY72nIMWerkwC7gHCV2MzDsqFYj0yqv3kx3VwzWTDttafEpWo7iCS1FGe5OqhO-2Bd3jCevb3HRW2K7uMI-2BHoVMKJYPHTcb1-2BeokLCnkg4GF4ESd2OMjmYVa9YqlKUKnbQFphseROpUHRJRvt9a7Gvi1-2ByA4iOOw-3D-3D) in the Company’s Form 10-Q, which has been filed with the Securities and Exchange Commission.

**Conference Call**

The Company will host a conference call on Friday, November 11, 2022, at 8:00 AM ET to discuss the company’s corporate progress and other developments.

The conference call will be available via telephone by dialing toll-free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and using entry code 849908. A webcast of the call may be accessed at [https://www.webcaster4.com/Webcast/Page/2585/47112](https://click.agilitypr.delivery/ls/click?upn=UbtWP9mxrAkz4-2Bt4ix9ULCmFWwZdnFtxfDAeRaCMLDMdFqUEgQsKgcJtA0IQQ9JCgu4SWywnBoMoSVsjfCcMn6J6CKMDHuEyhXZhsC-2ByDXJYPYOxsQPXFoflU1VjGXHLQdGQIQbnAKv-2Fw81TWXS3nLWVmGP1HZNwx7t5D1RLsZ7WFs2VGZmzY0nFutInZWMBLw32NAeVLw8wBOeZK2-2FSMRJVpkNuuMOTmENhOnPwhYW2yfCDCCPz4WpbERHifoQpkSThvisRMIsDJsw51zCJoRINx02-2BiExjnwHzG1zqqS2YMeA3zYHFbD-2F0Bnq8-2B-2BKhTFt8_znnZXbWgCmE6yyN6uT5fSc4ButwtT0xdWiNHb-2B0VwM8HtF55HA6-2FW4jtQLZIHeIwySlA7p66Ret-2BKrINhFbOjX3Fn4dO1sNMhND1d7bv9xX965ZdQy07JizLtLy9rRj4i53HT-2BHJIiDoNz4o3-2BxJ56-2BaEyV6F3lZD0w-2FPQ-2BBAfqgPGyMyTUiksuKBKvtFUiE7pCmX29XBqlIyqygoKD87RXGA6o1RTKGLqt2QW7AcOglwmA0TQrezYMYFVi19WtZ8UuLwu4Q1qYGPOlNRFagOe-2F4Xl-2Fdc2p54hpLXDpx-2BWsX5DzAU6px-2FpdISG53aq6EPndEDNQTm0sa-2FfWxjVsV-2BO9u-2BFMEivb2VCdzoQrinBR-2Fu131byWhBOveOcxub-2FD5VVQcw334CQI2FeWCKllt5V7-2BBA0sM92O7qZO6uud5Yrw5zYpluNH2vsSex7tFlYSrszUiVYG-2BltA2x7h-2BkwtkQ-3D-3D) or on the Company’s Investor Events section of the website [here](https://click.agilitypr.delivery/ls/click?upn=UbtWP9mxrAkz4-2Bt4ix9ULCmFWwZdnFtxfDAeRaCMLDMdFqUEgQsKgcJtA0IQQ9JCu5lpPdxuqolNkAzmW3wRXXZboxUZFfN7yvsJXuURWrdDSfuF1X2txJcJpZ81e1QWxsD6SlEVSd4yn-2BOdG-2Fiyy1sWB-2Fp-2BVilfrxnoi2X5MWYjJsEGY3-2FB79i57Wyb6mzXyUT3_znnZXbWgCmE6yyN6uT5fSc4ButwtT0xdWiNHb-2B0VwM8HtF55HA6-2FW4jtQLZIHeIwySlA7p66Ret-2BKrINhFbOjX3Fn4dO1sNMhND1d7bv9xX965ZdQy07JizLtLy9rRj4i53HT-2BHJIiDoNz4o3-2BxJ56-2BaEyV6F3lZD0w-2FPQ-2BBAfqgPGyMyTUiksuKBKvtFUiE7pCmX29XBqlIyqygoKD87RXGA6o1RTKGLqt2QW7AcOglwmA0TQrezYMYFVi19WtZ8UuLwu4Q1qYGPOlNRFagOXBg7dIWwJDm1LvDF44O4tw6XKirGwCHxlHW6GHqWPmuVfunMo5NmQvySn9I02kZYhoIsmfxSG9stcYBRN5yjneZDVZ60nTZRPBEu7TmxEJvR7ZZlF30CsmddjBzT2-2B-2FiC7nLDdTAhfDGwdZp7IAe5uJ8AIXFiP-2Brfq60uGAb94vI1-2FXO1cyn6VgxWbYM6BfaA-3D-3D).

A webcast replay will be available on the Company’s Investor Events section of the website ([https://ir.orgenesis.com/events#/](https://click.agilitypr.delivery/ls/click?upn=UbtWP9mxrAkz4-2Bt4ix9ULCmFWwZdnFtxfDAeRaCMLDMdFqUEgQsKgcJtA0IQQ9JCgu4SWywnBoMoSVsjfCcMn3f-2BXa3s3vLnE9hUjnSx4PWqDJinAuTygg1cFhJ8VCSCWwzUWFqvZ5wosG4yoa36mWU9Eh-2FRarzrwTnzGo-2FW6YbBJ2HrSt7VL4yl-2F1afCwEjzAxA6eXW8RdG24-2BX3Jmgu-2FrjCqBDOBdoK-2Btu0hsdBDEvza9eIUaVODxJ2N3M9HSu9jyn_znnZXbWgCmE6yyN6uT5fSc4ButwtT0xdWiNHb-2B0VwM8HtF55HA6-2FW4jtQLZIHeIwySlA7p66Ret-2BKrINhFbOjX3Fn4dO1sNMhND1d7bv9xX965ZdQy07JizLtLy9rRj4i53HT-2BHJIiDoNz4o3-2BxJ56-2BaEyV6F3lZD0w-2FPQ-2BBAfqgPGyMyTUiksuKBKvtFUiE7pCmX29XBqlIyqygoKD87RXGA6o1RTKGLqt2QW7AcOglwmA0TQrezYMYFVi19WtZ8UuLwu4Q1qYGPOlNRFagOX1BLuPAo4W6CLJxoVz9Fi87fgFu2um9MqTOkoWa-2F9DF85XJQMMgm4uI9FlU-2BFZQI2T7Qi3OWz14H4L0-2B4q003y-2BUc7PVNfYg1UuweZaG-2BZDWOxTtlcsJQb-2BVtV8MIPb-2Foes2wcxpGq-2B0tVnvSnVk1xNRMhG1Yg9rRQ-2FbYxcsGzJsRMX-2B6VVwoOc1SYpo7Bwmw-3D-3D)) through Saturday, November 11, 2023. A telephone replay of the call will be available approximately one hour following the call, through Friday, November 25, 2022 and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331for international callers and entering conference ID: 47112.

**ENDS**

**About Orgenesis**

Orgenesis is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format at the point of care. The Orgenesis POCare Platform is comprised of three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. Orgenesis identifies promising new therapies and leverages its POCare Platform to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production. The POCare Network brings together patients, doctors, industry partners, research institutes and hospitals worldwide to achieve harmonized, regulated clinical development and production of the therapies. [www.orgenesis.com](https://click.agilitypr.delivery/ls/click?upn=UbtWP9mxrAkz4-2Bt4ix9ULCmFWwZdnFtxfDAeRaCMLDMdFqUEgQsKgcJtA0IQQ9JC4koFruHsbyTI1ZGa2MxGiz6fXOikOiDRET-2FKxLaUoQzbKh79c4ACXvLh1OeM0NoDQqcuqqdG4nikRtVMShK-2F8b88i3gH4PKJjuiwcYXrEDADVca-2B2Jw1XLR6hAOIkSgsYXcK_znnZXbWgCmE6yyN6uT5fSc4ButwtT0xdWiNHb-2B0VwM8HtF55HA6-2FW4jtQLZIHeIwySlA7p66Ret-2BKrINhFbOjX3Fn4dO1sNMhND1d7bv9xX965ZdQy07JizLtLy9rRj4i53HT-2BHJIiDoNz4o3-2BxJ56-2BaEyV6F3lZD0w-2FPQ-2BBAfqgPGyMyTUiksuKBKvtFUiE7pCmX29XBqlIyqygoKD87RXGA6o1RTKGLqt2QW7AcOglwmA0TQrezYMYFVi19WtZ8UuLwu4Q1qYGPOlNRFagOTWw2KYZ3832hgeiFxjiBg5IMp16L9kv3f0RKw-2FyPH7Sdilz6F-2Bk88Qls0qrtlSBQC1JYc-2Fy6X1460FFp5XtLV57dgxuvSyPCGr1ygDxHRkMLUN8F2lboXDpU-2FDYgDg-2F-2BxVMDhNCXoZ4yMpWoIFN6VbW8VX6DDk2J6vLOzSf0Ft7TBlb-2BTbYnUU6JYPC6ZYMTA-3D-3D).

**Notice Regarding Forward-Looking Statements**

*This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, our reliance on, and our ability to grow, our point-of-care cell therapy platform and OMPUL business, our ability to achieve and maintain overall profitability, our ability to manage our research and development programs that are based on novel technologies, our ability to control key elements relating to the development and commercialization of therapeutic product candidates with third parties, the timing of completion of clinical trials and studies, the availability of additional data, outcomes of clinical trials of our product candidates, the potential uses and benefits of our product candidates, our ability to manage potential disruptions as a result of the COVID-19 pandemic, the sufficiency of working capital to realize our business plans and our ability to raise additional capital, the development of our POCare strategy, our trans differentiation technology as therapeutic treatment for diabetes, the technology behind our in-licensed ATMPs not functioning as expected, our ability to further our CGT development projects, either directly or through our JV partner agreements, and to fulfill our obligations under such agreements, our license agreements with other institutions, our ability to retain key employees, our competitors developing better or cheaper alternatives to our products, risks relating to legal proceedings against us and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.*